A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects
Latest Information Update: 29 Aug 2022
Price :
$35 *
At a glance
- Drugs Sitravatinib (Primary) ; Famotidine; Pantoprazole
- Indications Gastro-oesophageal reflux; Peptic ulcer
- Focus Pharmacokinetics
- Sponsors Mirati Therapeutics
- 24 Aug 2022 Status changed from active, no longer recruiting to completed.
- 29 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2021 Status changed from not yet recruiting to recruiting.